Nereus raises $20 million as mid-stage lung cancer trial shows promise
This article was originally published in Scrip
Executive Summary
Nereus Pharmaceuticals, which recently completed enrolment in a Phase II lung cancer trial with its lead candidate plinabulin (NPI-2358), has raised $20 million in a financing round led by HBM BioVentures.